Gilead Sues Sigmapharm Over Hepatitis B Generic

Law360, New York (October 4, 2010, 4:13 PM EDT) -- Gilead Sciences Inc. has sued Sigmapharm Laboratories LLC over its attempt to introduce a generic version of chronic hepatitis B drug Hepsera despite two patents covering the treatment.

In a complaint filed Friday in the U.S. District Court for the Eastern District of Pennsylvania, Gilead claims Bensalem, Pa.-based Sigmapharm has sought approval from the U.S. Food and Drug Administration to manufacture a generic form of Hepsera before the expiration of the patents-in-suit.

By dint of its abbreviated new drug application Sigmapharm has alleged that the two...
To view the full article, register now.